estimated that 93% of high grade glioma cases expressed at least one of IL13Rα2, HER2 or EGFR antigens (72% at least two) (99).This makes multitargeting as a clear path forward for enhancing therapeutic efficacy, with approaches targeting multiple pathways simultaneously already being evaluated in both clinical and preclinical trials (26, 92, 100–104). The gene discussed is EGFR; the disease is central nervous system cancer.